The Department of Health and Social Care (DHSC) issued a medicine supply notification (MSN) for Isosorbide mononitrate 60mg modified-release tablets and capsules on 27 August 2024.
No new patients should be initiated on Chemydur® 60XL, Monomax® XL, Monomil® XL 60mg modified-release tablets or Nyzamac® SR 60mg capsules until the supply issues have resolved.
Isotard® 60XL, Medomon® XL, Relosorb® XL and Tardisc® XL 60mg tablets remain available and can support the increased demand.
Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should:
- consider prescribing isosorbide mononitrate 60mg modified-release tablets generically, to enable any available brand to be dispensed, where appropriate; or
- consider prescribing an available alternative brand of isosorbide mononitrate 60mg modified-release tablet, and
- take into account patient history and previous hypersensitivity, or adverse reactions if prescribing an alternative brand.
Patient reassurance may be needed when switching between brands of isosorbide mononitrate modified release.
Prescribers should counsel patients on the change and possible adverse events they may experience, particularly in the first few days, the most important being hypotension, tachycardia, and worsening headaches. If they have concerns, patients should be advised to contact their doctor.
Refer to the MSN below for full supporting information and the SPS Medicines Supply Tool (needs a login).
Please note that the updated MSN was issued to include Serious Shortage Protocols SSP073-SSP076.
